Roche and Genentech announce new clinical trial to begin early next year - Generation HD2 - to explore the use of tominersen in younger, less symptomatic HD patients. Click here…
Roche Restarts Redesigned Phase 3 Huntington’s Disease Trial
Read more about this at the At Risk for Huntington's Disease Blog
Roche Phase 3 Clinical Trial for Huntington’s Disease Gene-Silencing Drug to Enroll Volunteers – Early 2019
Dear friends in the fight against Huntington's disease, Pharma giant Roche expects to start enrolling subjects worldwide (including the U.S.) in early 2019 in its historic Phase 3 clinical trial…
Statement from Roche and AAN Huntington’s Community
Statement from Roche and AAN Huntington's Community as originally reported on We Have a Face Global Times, read more here.